The cost effectiveness of Intra-Articular Hyaluronic Acid (IAHA) and Disease-Modifying Drugs (DMOADs) used in the treatment of knee OA

Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis.

Article specifications

This review study was published in 2018 in Journal of Pharmacoeconomics. (IF 2013: 3.338) by French specialists. A systematic literature searches of the MEDLINE, Scopus, EMBASE and Cochrane databases was performed independently by two rheumatologists who used the same predefined eligibility criteria to identify relevant articles. A total of 95 abstracts were selected, and 13 articles were considered for the review: nine articles on IAHA and four on DMOADs. Only one article directly compared different IAHA compounds.

 

Result

This review highlights substantial heterogeneity between studies, ranging from a cost saving (or dominating) position to very high ICERs, far above the acceptability threshold of €50,000/QALY. Additional research is needed to determine reliable and robust ICER estimates for knee OA therapies.